» Articles » PMID: 107509

Pyruvate Carboxylase and Phosphoenolpyruvate Carboxykinase Activity in Leukocytes and Fibroblasts from a Patient with Pyruvate Carboxylase Deficiency

Overview
Journal Pediatr Res
Specialties Biology
Pediatrics
Date 1979 Jan 1
PMID 107509
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Normal values are given for the activities of pyruvate carboxylase (E.C.6.4.1.1), mitochondrial phosphoenolpyruvate carboxykinase (E.C. 4.1.1.32, PEPCK), and citrate synthase (E.C. 4.1.3.7) in fibroblasts, lymphocytes, and leukocytes. Also given are values for these enzymes in the leukocytes and fibroblasts from a severely mentally and developmentally retarded patient with proximal renal tubular acidosis and hepatic, cerebral, and renal cortical pyruvate carboxylase deficiency. In normals, virtually all of the mitochondrial PEPCK and pyruvate carboxylase activity was present in the mononuclear leukocyte fraction of whole venous blood. Cellular fractionation studies with human lymphocytes and fibroblasts demonstrated that all of the PEPCK activity in these cells is mitochondrial. Normal values for pyruvate carboxylase in leukocytes were 0.092 (0.070--0.208) mU/mg protein (n=5), in lymphocytes 0.154 (0.092--0.262) mU/mg protein (n=5), and in fibroblasts 1.36 (0.778--2.19) mU/mg protein (n=5). The patient with hepatic, renal, and cerebral pyruvate carboxylase deficiency had no detectable activity (less than 0.009 mU/mg protein) in his leukocytes and 0.018 mU/mg protein in his fibroblasts. Data from an assay for pyruvate carboxylase activity in the patient's fibroblasts show that the activity observed is significant but very close to the lower limits of the assay. Values for PEPCK in normal lymphocytes were 1.42 (0.824--1.88) mU/mg protein (n=5), in leukocytes 1.68 (1.64--1.72) mU/mg protein (n=2), and in fibroblasts 5.49 (3.94--6.33) mU/mg protein (n=6).

Citing Articles

Development of simple and effective PCR based assay to detect mutation (c.425G > A) among Saudi carriers and functional study of the homozygous mutations.

Al-Asmari A, Peer-Zada A, Aldehaimi A, Polychronakos C, Chentoufi A Saudi J Biol Sci. 2022; 29(12):103461.

PMID: 36211601 PMC: 9535431. DOI: 10.1016/j.sjbs.2022.103461.


Cerebral Gluconeogenesis and Diseases.

Yip J, Geng X, Shen J, Ding Y Front Pharmacol. 2017; 7:521.

PMID: 28101056 PMC: 5209353. DOI: 10.3389/fphar.2016.00521.


Succinyl-CoA synthetase (SUCLA2) deficiency in two siblings with impaired activity of other mitochondrial oxidative enzymes in skeletal muscle without mitochondrial DNA depletion.

Huang X, Bedoyan J, Demirbas D, Harris D, Miron A, Edelheit S Mol Genet Metab. 2016; 120(3):213-222.

PMID: 27913098 PMC: 5346465. DOI: 10.1016/j.ymgme.2016.11.005.


Three rare diseases in one Sib pair: RAI1, PCK1, GRIN2B mutations associated with Smith-Magenis Syndrome, cytosolic PEPCK deficiency and NMDA receptor glutamate insensitivity.

Adams D, Yuan H, Holyoak T, Arajs K, Hakimi P, Markello T Mol Genet Metab. 2014; 113(3):161-70.

PMID: 24863970 PMC: 4219933. DOI: 10.1016/j.ymgme.2014.04.001.


Transcarboxylase 5S structures: assembly and catalytic mechanism of a multienzyme complex subunit.

Hall P, Zheng R, Antony L, Pusztai-Carey M, Carey P, Yee V EMBO J. 2004; 23(18):3621-31.

PMID: 15329673 PMC: 517613. DOI: 10.1038/sj.emboj.7600373.